首页> 外文期刊>Journal of Market Access & Health Policy >Filling the gap in CNS drug development: evaluation of the role of drug repurposing
【24h】

Filling the gap in CNS drug development: evaluation of the role of drug repurposing

机译:填补中枢神经系统药物开发的空白:评估药物再利用的作用

获取原文
       

摘要

Background and objective: Background and objective: Drug repurposing has been considered a cost-effective and reduced-risk strategy for developing new drugs. Little is known and documented regarding the efficiency of repurposing strategies in drug development. The objective of this article is to assess the extent and meaning of this process in the CNS area.Methods: In order to identify repurposed drugs that target the CNS, an extensive search was performed. For each identified case, its initial and target indication, development status and the type of repurposing strategy (repositioning, reformulation or both) was recorded.Results: One hundred and eighteen source products were identified. They were repurposed (mainly repositioned) 203 times with 81 products repurposed once and 38 products repurposed twice or more. The highest number of source drugs originated from the CNS area. Alzheimer’s disease was targeted most often. Half of the new indications were approved. Regarding repurposing within the ...
机译:背景和目标:背景和目标:药物再利用已被认为是开发新药物的经济有效且风险较低的策略。关于重新开发药物开发策略的效率知之甚少,并没有文献记载。本文的目的是评估该过程在中枢神经系统领域的程度和意义。方法:为了确定靶向中枢神经系统的改用药物,进行了广泛的搜索。对于每个确定的病例,记录其最初和目标指示,发展状况以及重新调整策略的类型(重新定位,重新制定配方或两者)。结果:共鉴定出118种产品。他们进行了203次更改(主要是重新定位)的用途,其中81个产品更改了一次用途,38个产品更改了两次或更多次。来自CNS地区的来源药物数量最多。阿尔茨海默氏病是最常见的疾病。新适应症的一半被批准。关于重新定位...

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号